SIRNAOMICS’ Post

Biocon Biologics Shares Promising Results from Phase-III Trials at #EADVCongress2024 #BioconBiologics presented encouraging data from two Phase-III clinical studies at the European Academy of Dermatology and Venereology (EADV) Congress 2024, focusing on #Biosimilar versions of #Adalimumab and #Ustekinumab for treating #ChronicPlaquePsoriasis. The studies demonstrated the #Safety and #Efficacy of switching between adalimumab and its #Biosimilar, #Adalimumab-fkjp, without compromising treatment outcomes. Additionally, the trials confirmed the biosimilarity of #Bmab 1200 to #Ustekinumab, suggesting potential #Interchangeability and improved #PatientAccess to these therapies. Biocon's Chief Medical Officer, Uwe Gudat, highlighted that the data supports the interchangeability of adalimumab-fkjp, enhancing treatment flexibility and reducing #HealthcareCosts. Both studies met the FDA's standards for biosimilar interchangeability, marking a significant step toward greater #Access to effective #Treatments for #Psoriasis patients. #BioconBiologics #Biosimilars #EADV2024 #Psoriasis #HealthcareInnovation #BiosimilarInterchangeability #Adalimumab #Ustekinumab #PatientCare #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #ConferenceCoverage #PortfolioOptimization Detailed News: https://shorturl.at/mMKdo Follow our page for more industry updates: https://lnkd.in/de5zNWmK

🎯 Sandoz, a division of Novartis, achieves a significant milestone with positive results from the MYLIGHT Phase III study for its biosimilar aflibercept. The study demonstrates therapeutic equivalence in visual acuity improvement compared to the reference biologic, Eylea. These findings mark a crucial advancement towards regulatory approval for this much-needed treatment option in #ophthalmology 👉 Find out more in this article from Ophthalmology Times by Hattie Hayes #AMD #HealthcareInnovation #EyeHealth #EyeSurgery #Biotech #Medtech #Lifescience

ANNOUNCEMENT February 2024: Cassderma Rx has completed the first round of pre-clinical wound-healing studies that helped us select our formulation.  The studies showed improvement in wound-healing for our formulations relative to no-treatment control.  No safety issues were observed.   Cassderma Rx is making great progress towards helping individuals suffering from non-healing chronic wounds, which is still classified a global unmet need.    Check out this newly published review by the NIH: “Why Are There So Few FDA‑Approved Therapeutics for Wound Healing?” https://lnkd.in/dYrSzbqM #research, hashtag #fda, hashtag #skin, hashtag #wounds, hashtag #dermatology, hashtag #pressureulcers, hashtag #burns, hashtag #diabetes

Our recent publication, "Comprehensive Pharmacokinetic Evaluation of High Melanin Binder Levofloxacin in Rabbits," has just been released in Investigative Ophthalmology & Visual Science! This study highlights the potential of topical eye drops for treating posterior eye segments, showing promising results for non-invasive ocular drug delivery. In collaboration with Paulina Jakubiak-Fort, Ruben Alvarez, Antonello Caruso, Leuthardt Monika, Senn Claudia, and Eva Maria del Amo Páez, as well as Prof. Arto Urtti. Thanks for your guidance and support. 🔗 Check out the full study here: https://lnkd.in/dwh9XcMB #pharmacokinetics #ocular #melaninbinding #eyedrops #noninvasive #roche #UEF

Triveni Bio has successfully secured $115 million in Series B financing to advance their innovative pipeline targeting immunological and inflammatory (I&I) disorders. Key points: 1. Funding led by Goldman Sachs Alternatives, with participation from Fidelity Management & Research Company, Deep Track Capital, and existing investors. 2. Primary focus: Advancing TRIV-573, a second-generation anti-kallikrein 5/7+IL-13 bispecific antibody, through clinical proof-of-concept. 3. Lead candidate TRIV-509 (monoclonal antibody inhibitor targeting KLK 5/7) on track for IND submission in Q1 2025. 4. Expansion of data science platform, emphasizing precision dermatology. 5. Development of trypsin 1 and 2 inhibitor for hereditary pancreatitis, addressing an unmet medical need. Questions for discussion: - How might the combination of KLK 5/7 inhibition with IL-13 targeting in TRIV-573 potentially overcome current limitations in treating atopic dermatitis? - What are your thoughts on the increasing role of data science in precision dermatology, and how might this impact future therapeutic developments? - Given the lack of approved treatments for hereditary pancreatitis, what challenges and opportunities do you foresee in Triveni's pursuit of a trypsin 1 and 2 inhibitor for this indication? #BiotechInnovation #ImmunologyResearch #PrecisionMedicine #SeriesBFunding

What are your thoughts on Triveni Bio's approach to precision dermatology and their work on hereditary pancreatitis? Check out our post below for more details and join the discussion 😊

Genemarkers, a CAP/CLIA lab, provides clinical biomarker analysis to support early and late-stage clinical trials, with expertise in dermatology, neuroscience, pain management, and other therapeutic areas. Contact us to get started. https://lnkd.in/eQZyQWVS #MolecularBiology #PGxTesting #Pharmacogenomics #ClinicalTrials #ClinicalResearch #PreClinicalResearch #Biology #Pharma #Pharmaceuticals #DrugDevelopment

Some data coming out of #2024AAD Annual Meeting #LateBreakers on the TYK2 landscape; a potential 'best-in-class' from Alumis: ➕ Positive data readout on their 💊 oral ESK-001, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, results include: 📈 increasing PASI over time ⬆ high efficacy; favorable safety/tolerability Phase 3️⃣ program to initiate later this 📆 year. https://lnkd.in/e9B8WHf4 #2024AAD #LateBreaker #AmericanAcademyOfDermatology #AnnualMeeting #Dermatology #Psoriasis #CompetitiveLandscape #ClinicalData #ImmuneMediatedDiseases #Innovation #Biotech #Pharma #Healthcare

NEJM Publishes Data on the Application of B-VEC to Treat Ocular Complications in Patients with DEB - Dermatology Times >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #biotech #competitivemarketing #pharmaceutical

𝐕𝐞𝐫𝐫𝐢𝐜𝐚 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐏𝐡𝐚𝐬𝐞 𝟐 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐨𝐫 𝐕𝐏-𝟑𝟏𝟓 𝐢𝐧 𝐁𝐚𝐬𝐚𝐥 𝐂𝐞𝐥𝐥 𝐂𝐚𝐫𝐜𝐢𝐧𝐨𝐦𝐚 Verrica Pharmaceuticals (Nasdaq: VRCA) Verrica Pharmaceuticals, a leader in dermatology therapeutics, announced positive preliminary results from Part 2 of its Phase 2 trial for VP-315, an oncolytic peptide for treating basal cell carcinoma (BCC). The trial showed over 50% complete histological clearance and a significant reduction in tumor size, with no dose-limiting toxicities. "We're encouraged by the results, which suggest VP-315 could be a game-changer for BCC treatment," said Ted White Ted White , CEO. The company plans to present full data at future medical meetings and seek further FDA guidance in 2025. #Dermatology #CancerResearch #Biotech #Oncology #SkinCancer #ClinicalTrials #Pharmaceuticals #BasalCellCarcinoma #Innovation #Healthcare